• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Accuray Incorporated

    10/31/25 4:01:42 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email
    S-8 1 aray-20251030.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on October 31, 2025

    Registration No. 333-______

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    ACCURAY INCORPORATED

    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or Other Jurisdiction of
    Incorporation or Organization)

     

    20-8370041

    (I.R.S. Employer
    Identification Number)


    ———————————————

     

    1240 Deming Way

    Madison, Wisconsin 53717

    (Address of Principal Executive Offices including Zip Code)

     

     

    Accuray Incorporated Stand-Alone Inducement Restricted Stock Unit Agreement

    Accuray Incorporated Stand-Alone Inducement Performance Unit Agreement

    (Full Title of the Plan)

     

     

    Stephen La Neve
    President and Chief Executive Officer
    Accuray Incorporated
    1240 Deming Way

    Madison, WI 53717
    (608) 824-2800

    Copy to:
    Katharine A. Martin

    Lisa L. Stimmell

    Wilson Sonsini Goodrich & Rosati, P.C.

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

    (Name and Address, Including Zip Code, and Telephone Number,
    Including Area Code, of Agent for Service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  Accelerated filer 

     

    Non-accelerated filer  Smaller reporting company 

     

    Emerging Growth Company 

     

     

     


     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents, which were filed with the Securities and Exchange Commission (the “Commission”), are incorporated herein by reference (excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)):

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, filed with the Commission on August 28, 2025 (File No. 001-33301) (including portions incorporated by reference to the Registrant’s Definitive Proxy Statement on Schedule 14A, as filed with the Commission on October 1, 2025);

     

    (b)
    The Registrant’s Current Reports on Form 8-K filed with the Commission (File No. 001-33301) on August 22, 2025, September 19, 2025, and October 20, 2025 (other than the portions of these documents not deemed to be filed); and

     

    (c)
    The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on February 7, 2007 (File No. 001-33301), including any subsequently filed amendments and reports updating that description.

     

    All documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to be a part of this Registration Statement. Information contained in a Current Report on Form 8-K furnished to the Commission will not be incorporated by reference into this Registration Statement.

    Item 4. Description of Securities

    The Common Stock being registered hereunder has been registered pursuant to Section 12 of the Exchange Act.

    Item 5. Interests of Named Experts and Counsel

    Not applicable.

    Item 6. Indemnification of Directors and Officers

    Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents under certain circumstances.

     

     


     

    As permitted by Section 102(b)(7) of the DGCL, the Registrant’s amended and restated certificate of incorporation contains provisions that limit the liability of its directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant’s directors will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

    •
    any breach of the director’s duty of loyalty to the Registrant or to its stockholders;
    •
    acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
    •
    unlawful payment of dividends or unlawful stock repurchases or redemptions; and
    •
    any transaction from which the director derived an improper personal benefit.

    The Registrant’s certificate of incorporation provides that it may indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director, officer, employee or agent of the Registrant or any predecessor of the Registrant, or serves or served at any other enterprise as a director, officer, employee or agent at the request of the Registrant or any predecessor to the Registrant.

    If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of the Registrant’s directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. The Registrant’s amended and restated certificate of incorporation does not eliminate a director’s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect a director’s responsibilities under any other laws, such as the federal securities laws or other state or federal laws.

    The Registrant’s amended and restated bylaws provide that the Registrant shall indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of the Registrant who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director, officer, employee or agent of the Registrant or is or was serving at the request of the Registrant as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such action, suit or proceeding.

    Further, the Registrant has entered into indemnification agreements with each of its current directors and officers. These agreements provide for the indemnification of the Registrant’s directors and officers for all reasonable expenses and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were the Registrant’s agents. The Registrant also maintains directors’ and officers’ liability insurance.

    Item 7. Exemption from Registration Claimed

    Not applicable.

    Item 8. Exhibits

     

     

     

     

     

     

     

    Exhibit No.

    Exhibit Descriptions

     

     

     

     

     

     

    4.1(1)

    Form of Common Stock Certificate.

     

     

     

     

     

    5.1(2)

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.

     

     

     

     

     

     

     


     

    23.1(2)

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1).

     

     

     

     

     

    23.2(2)

    Consent of Grant Thornton LLP, independent registered public accounting firm.

     

     

     

     

     

    24.1(2)

    Power of Attorney (contained on signature page hereto).

     

     

     

     

     

    99.1(2)

    Form of Accuray Incorporated Stand-Alone Inducement Restricted Stock Unit Agreement

     

     

     

     

     

    99.2(2)

    Form of Accuray Incorporated Stand-Alone Inducement Performance Unit Agreement

     

     

     

     

     

    107.1(2)

    Filing Fee Table

     

     

     

     

     

     

    (1)
    Incorporated by reference to Exhibit 4.3 filed with the Registrant’s Registration Statement on Form S-1/A (Registration No. 333-138622), filed with the Commission on February 5, 2007.
    (2)
    Filed herewith.

     

    Item 9. Undertakings

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee” table in the effective Registration Statement.

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange

     

     


     

    Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Madison, State of Wisconsin, on the 31st day of October, 2025.

     

    Accuray Incorporated

     

     

     

    By:

    /s/ Stephen La Neve

     

    Stephen La Neve
    President and Chief Executive Officer

     

     

     


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Stephen La Neve and Ali Pervaiz and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

     

    Title

     

     

    Date

     

    /s/ Stephen La Neve

    Stephen La Neve

     

    President and Chief Executive Officer and Director (principal executive officer)

     

    October 31, 2025

     

     

     

     

     

    /s/Ali Pervaiz

    Ali Pervaiz

     

    Chief Financial Officer (principal financial officer)

     

    October 31, 2025

     

     

     

     

     

    /s/ Joseph E. Whitters

    Joseph E. Whitters

     

    Chairperson of the Board and Director

     

    October 31, 2025

     

     

     

     

     

    /s/ Robert Kill

    Robert Kill

     

    Director

     

    October 31, 2025

     

     

     

     

     

    /s/ James M. Hindman

    James M. Hindman

     

    Director

     

     

    October 31, 2025

     

     

     

     

     

    /s/ Beverly A. Huss

    Beverly A. Huss

     

    Director

     

    October 31, 2025

     

     

     

     

     

    /s/ Anne b. Le Grand

    Anne B. Le Grand

     

    Director

     

     

    October 31, 2025

     

     

     

     

     

     

    Steven F. Mayer

     

    Director

     

     

    October 31, 2025

     

     

     

     

     

    /s/ Mika Nishimura

    Mika Nishimura

     

    Director

     

    October 31, 2025

     

     

     

     

     

    /s/ Byron C. Scott

    Byron C. Scott

     

    Director

     

    October 31, 2025

     

     

     


    Get the next $ARAY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Accuray Reports Fiscal 2026 First Quarter Financial Results

    MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2025. Key Highlights  On October 20, 2025, the Company announced accelerated transformation efforts, including:Appointed Steve La Neve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November 2025.Appointed Steven F. Mayer, a member of the Board of Directors, as the Transformation Board Sponsor to lead the Compan

    11/5/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

    MADISON, Wis., Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve, the company's new Chief Executive Officer. As a material inducement to Mr. La Neve joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Board of Directors of the company approved granting Mr. La Neve awards consisting of (i)1,500,000 restricted stock units covering shares of the company's common stock and (ii) 1,500,000 performance-based restricted stock units ("PSUs") covering shares of the company's common stock, in each case effective as of October 31, 2025 (the "Inducement Awards"). The

    10/31/25 4:03:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025

    MADISON, Wis., Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 5, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    10/28/25 7:35:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO La Neve Stephen R.

    4 - ACCURAY INC (0001138723) (Issuer)

    11/4/25 4:15:12 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider La Neve Stephen R.

    3 - ACCURAY INC (0001138723) (Issuer)

    11/4/25 4:10:07 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    VP, Corporate Controller Murphy Michael John covered exercise/tax liability with 12,001 shares and converted options into 37,500 shares (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    11/3/25 5:37:18 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Accuray with a new price target

    ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

    2/13/24 6:29:42 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on Accuray with a new price target

    B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    6/23/22 7:25:39 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on Accuray with a new price target

    Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

    12/22/21 4:56:14 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    SEC Filings

    View All

    SEC Form 10-Q filed by Accuray Incorporated

    10-Q - ACCURAY INC (0001138723) (Filer)

    11/5/25 4:16:35 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ACCURAY INC (0001138723) (Filer)

    11/5/25 4:11:03 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Accuray Incorporated

    S-8 - ACCURAY INC (0001138723) (Filer)

    10/31/25 4:01:42 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Whitters Joseph E bought $62,335 worth of shares (50,000 units at $1.25), increasing direct ownership by 9% to 611,053 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    6/16/25 4:10:10 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    5/30/24 4:10:11 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Financials

    Live finance-specific insights

    View All

    Accuray Reports Fiscal 2026 First Quarter Financial Results

    MADISON, Wis., Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2025. Key Highlights  On October 20, 2025, the Company announced accelerated transformation efforts, including:Appointed Steve La Neve as President and Chief Executive Officer. He succeeds Suzanne Winter, who will retire after six years of service and remain in an advisory role through the end of November 2025.Appointed Steven F. Mayer, a member of the Board of Directors, as the Transformation Board Sponsor to lead the Compan

    11/5/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025

    MADISON, Wis., Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 5, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (interna

    10/28/25 7:35:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results

    Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2025, ended June 30, 2025. Key Fiscal Fourth Quarter Highlights Net revenue was $127.5 million, a decrease of 5 percent from the prior year period.Net income was $1.1 million compared to net income of $3.4 million in the prior year period.Adjusted EBITDA was $9.4 million compared to $10.1 million in the prior year period.Order book-to-bill at 1.2Key Fisca

    8/13/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth

    Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEOCompany Appoints Steven F. Mayer as Transformation Board SponsorChan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this work, the company's Board of Directors has appointed proven industry leaders with deep operational expertise to drive execution, strengthen performance, and enhance competitiveness. The transformation plan initiatives, most of which will be implemented during the current fisc

    10/20/25 9:20:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities

    MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares"). As part of the exchange consideration, Accuray will pay exchanging holders an aggregate of approximately $68.6 million in cash. The Exchange is expected to close on or about June 11, 202

    6/6/25 7:30:00 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    9/6/24 9:00:07 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Accuray Incorporated

    SC 13G - ACCURAY INC (0001138723) (Subject)

    2/13/24 4:56:01 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

    SC 13G/A - ACCURAY INC (0001138723) (Subject)

    2/13/24 11:19:22 AM ET
    $ARAY
    Medical/Dental Instruments
    Health Care